Poisons Standard June 2017

Administered by Department of Health, Disability and Ageing

Legislation au F2017L00605 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Subject:           Therapeutic Goods Act 1989

Poisons Standard June 2017

 

The Therapeutic Goods Act 1989 (the TG Act) provides for the establishment and maintenance of a system of controls for the quality, safety, efficacy and timely availability of therapeutic goods that are used in Australia or exported from Australia.  The TG Act also provides for a framework for the state and territory governments to adopt a uniform approach to control the availability and accessibility, and to ensure the safe handling, of medicines and poisons in Australia.  The Therapeutic Goods Administration (the TGA), which is part of the Department of Health, is responsible for administering the TG Act.

Part 6-3 of the TG Act provides the basis for a uniform system of access controls for goods containing scheduled substances.  The scheduling of substances allows restrictions to be placed on their supply to the public, in the interests of public health and safety.  The scheduling of substances is aimed at minimising the risks of poisoning from, and the misuse or abuse of, scheduled substances.

Subsection 52D(2) of the TG Act (which is in Part 6-3) provides for the Secretary of the Department of Health, to amend the current Poisons Standard (known as the Standard for the Uniform Scheduling of Medicines and Poisons) or to prepare a document (a new Poisons Standard) that includes schedules containing the names or descriptions of substances, in substitution for the current Poisons Standard.

The Poisons Standard consists of decisions of the Secretary, regarding the classification of poisons into the different Schedules, signifying the degree of control recommended to be exercised over their availability to the public.

The TG Act establishes two expert advisory committees, the Advisory Committee on Medicines Scheduling (the ACMS) (section 52B) and the Advisory Committee on Chemicals Scheduling (the ACCS) (section 52C), which provide advice and make recommendations to the Secretary on matters relating to medicines and chemicals scheduling decisions.

The Schedules contained in the Poisons Standard are referred to under state and territory legislation for regulatory purposes.  This enables restrictions to be placed on the supply of scheduled substances to the public, according to the degree of risk associated with them and the degree of control over their availability, in the interest of public health and safety.

The Commonwealth also takes into account the scheduling and classification of substances in the Poisons Standard for regulatory and enforcement purposes under the TG Act.

 

For example, the TG Act prohibits the publication or broadcasting of advertisements to consumers about prescription medicines containing substances included in Schedule 4 or 8 of the Poisons Standard, or over the counter medicines containing substances included in Schedule 3 and not included in Appendix H of the Poisons Standard.  The advertising of substances included in Schedule 9 or Schedule 10 of the Poisons Standard is also prohibited.

The Scheduling Policy Framework (the SPF) provides guidance on whether a decision concerning the Poisons Standard would benefit from being referred to ACMS or ACCS for advice.  A copy of the SPF can be found at https://www.tga.gov.au/publication/ahmac-scheduling-policy-framework-medicines-and-chemicals.

The purpose of this instrument is to make a new Poisons Standard (cited as the Poisons Standard June 2017) in substitution for the previous Poisons Standard - the Poisons Standard February 2017 (which commenced on 1 February 2017).

The Poisons Standard June 2017 incorporates a number of changes to the Poisons Standard February 2017. These amendments principally involve changes to existing entries, and the inclusion of a number of specified substances in the Poisons Standard for the first time.

A number of these changes were made following the provision of advice from the ACCS and/or the ACMS, in accordance with the procedures set out in Subdivision 3D.2 of Part 6 of the Therapeutic Goods Regulations 1990 for amending the Poisons Standard when a proposed amendment is referred to an expert advisory committee.

Public comment was invited on those matters referred to the March 2016 ACCS meeting and the November 2016 ACMS, ACCS and Joint ACCS-ACMS meetings. These meetings related to proposals to amend the Poisons Standard in relation to the following substances:

          Bis-Isobutyl PEG/PPG- 20/35/Amodimeticone Copolymer

          p-Aminophenol

          2-Methylresorcinol

          Abamectin

          Pegbovigrastim

          Fennel oil

          Guanfacine

          Tianeptine

          Paracetamol compounded with caffeine

          Vitamin D

          Cetirizine

          Panobinostat

          Ceritinib

          Olaparib

          Brivaracetam

          Follitropin delta

The invitation to comment on bis-isobutyl PEG/PPG-20/35/amodimeticone copolymer, 2-methylresorcinol and p-aminophenol was advertised on the TGA website (https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acms-and-accs-meetings-march-2016) on 20 January 2016, and closed on 18 February 2016.

The invitation to comment in relation to abamectin, pegbovigrastim, guanfacine hydrochloride and tianeptine were advertised on the TGA website (https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-accs-and-acms-meetings-november-2016) on 22 September 2016, and closed on 20 October 2016.

The invitation to comment on fennel oil, paracetamol compounded with caffeine, vitamin D, cetirizine, panobinostat, ceritinib, olaparib, brivaracetam and follitropin delta was advertised on the TGA website (https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acms-meeting-november-2016) on 4 August 2016, and closed on 1 September 2016.

Further public comment was subsequently invited on the delegates’ interim decisions on 12 May 2016 with a closing date of 26 May 2016; and on 2 February 2017 with a closing date of 16 February 2017.

The delegates’ final decisions in relation to these matters were published on the TGA website on 23 June 2016, 27 October 2016, and 23 March 2017, with the delegate deciding that each of these decisions should be implemented from 1 June 2017.

Other amendments set out in this instrument added a number of new substances to the Poisons Standard for the first time: dengue vaccine, meningococcal group B vaccine, sodium phenylbutyrate, silodosin, sebelipase alfa and brexpiprazole.

These decisions were delegate-only decisions that were not open to public consultation, as they were considered (in accordance with the SPF) to be sufficiently straightforward as to not require public consultation. For some of these previously unscheduled substances, consultation in relation to scheduling was undertaken with the sponsor of the substance.

The Poisons Standard June 2017 also includes a number of editorial amendments, including corrections of typographical errors and amendments to update the names of various medicines and chemicals listed on the TGA’s website (www.tga.gov.au) to bring those more into line with the names used for those substances internationally (https://www.tga.gov.au/updating-medicine-ingredient-names). Some examples of editorial amendments in the Poisons Standard June 2017 include:

  • adding a cross reference to para-amidopropiophenone (PAPP) in the index entry for 4-aminopropiophenone;
  • amending a typographical error in the index entry for pentobarbital;
  • amending typographical errors for potassium bromate, potassium chlorate, phenols, pentachlorophenols and mesosulfuron-methyl;
  • adding a cross reference to sassafras oil in the index entry for safrole;
  • replacing Follitropin alpha’ with ‘follitropin alfa’; and
  • replacing methylamfetamine with metamfetamine and adding a cross reference to methylamfetamine and methamphetamine for metamfetamine.

These decisions were not open to public consultation as they were considered, in accordance with the SPF, to be sufficiently straightforward as to not require public consultation.

The Poisons Standard is a legislative instrument for the purposes of the Legislation Act 2003 (the LA). However, section 42 (disallowance) of the LA does not apply (refer to subsection 52D(4A) of the TG Act). Because it is not disallowable, subsection 9(1) of the Human Rights (Parliamentary Scrutiny) Act 2011 does not require that the instrument be accompanied by a statement of compatibility with the human rights recognised under that Act.

The instrument commences on 1 June 2017, which means the Poisons Standard June 2017 is effective on and from that day.

Overview

The Therapeutic Goods Act 1989 (TG Act) serves to establish and maintain a system of controls over the quality, safety, efficacy, and timely availability of therapeutic goods in Australia, whether used domestically or exported. The Act also provides a framework for state and territory governments to adopt a uniform approach to the control of the availability, accessibility, and safe handling of medicines and poisons across the country. Administered by the Therapeutic Goods Administration (TGA), a part of the Department of Health, the TG Act seeks to minimise the risks of poisoning and misuse or abuse of scheduled substances by implementing a system of access controls. To this end, the Act allows for the scheduling of substances, which is intended to control their supply to the public according to the level of risk they pose. The Poisons Standard, which includes schedules detailing substances and the degree of control recommended over their availability, is referenced in state and territory legislation for regulatory purposes. The Poisons Standard June 2017, introduced as a replacement for the Poisons Standard February 2017, incorporates various changes to existing entries and includes new substances, following advice from expert committees and public consultations. The changes aim to refine the classification of substances to better align with international standards and to improve the safety and efficacy of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 provides the legislative framework for regulating therapeutic goods in Australia, including medicines and poisons. The Act applies to all therapeutic goods that are manufactured, supplied, or advertised in Australia, as well as those that are exported from Australia. The Act establishes a system of controls to ensure the quality, safety, efficacy, and timely availability of these goods. It also provides for a uniform approach to controlling the availability and accessibility of medicines and poisons across the states and territories. The Therapeutic Goods Administration, a part of the Department of Health, is responsible for administering the Act. The Act's application is extended through the Poisons Standard, which classifies substances into various schedules based on the degree of control required over their availability to the public. These schedules are referenced in state and territory legislation to implement restrictions on the supply of scheduled substances, aiming to minimise risks associated with their misuse or abuse. The Act also prohibits advertising of certain scheduled substances to consumers, ensuring public health and safety. The Act does not apply to substances that are not classified as therapeutic goods or to those activities that do not involve the supply of therapeutic goods within Australia. The Poisons Standard June 2017, which replaces the previous Poisons Standard, incorporates changes to existing entries and introduces new substances, reflecting decisions made by expert advisory committees and public consultations.

Key Provisions

The main operative sections of the Poisons Standard June 2017, as outlined in the Explanatory Statement, pertain to the scheduling of substances and the regulation of therapeutic goods in Australia. Section 52D(2) of the Therapeutic Goods Act 1989 (the TG Act) allows the Secretary of the Department of Health to amend the Poisons Standard or prepare a new one, detailing the schedules of substances that require varying degrees of control over their availability to the public. The Poisons Standard June 2017, therefore, includes schedules of substances and updates to the classification of certain therapeutic goods. The Act also establishes expert advisory committees, the Advisory Committee on Medicines Scheduling (section 52B) and the Advisory Committee on Chemicals Scheduling (section 52C), which provide advice to the Secretary on scheduling decisions. The obligations imposed by the Act on parties or entities it governs primarily involve compliance with the scheduling of substances as outlined in the Poisons Standard June 2017. Manufacturers, suppliers, and retailers of therapeutic goods must ensure that they adhere to the restrictions on the supply of scheduled substances, which vary depending on the degree of risk associated with each substance. For instance, the Act prohibits advertising certain prescription and over-the-counter medicines containing substances from specific schedules, such as Schedule 4, 8, 9, or 10 of the Poisons Standard. Furthermore, the Act mandates that state and territory legislation references the Schedules in the Poisons Standard for regulatory purposes, ensuring that restrictions on the supply of scheduled substances are uniformly enforced across Australia. Breach of the provisions set out in the Poisons Standard June 2017 and the TG Act can result in various offences and penalties. For example, advertising prescription or over-the-counter medicines containing scheduled substances in contravention of the Act can lead to civil or criminal penalties. The specific penalties depend on the nature and severity of the offence, but can include fines and imprisonment. Additionally, non-compliance with the scheduling and classification of substances in the Poisons Standard for regulatory and enforcement purposes can also result in penalties under the TG Act. The maximum penalties for breaches of the Act are not explicitly stated in the Explanatory Statement, but they can vary depending on the specific offence and jurisdiction.

Legal classification tags

Area of Law
Environmental Law
Health Law
Consumer Law
Instrument
Regulation
Concepts
Definitions & Interpretation
Licensing & Registration
Reporting & Disclosure Obligations
Enforcement Powers
Prohibited Conduct

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.